# Brenus Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brenus-pharma

- Industry: Biotechnology
- Headquarters: Lyon, France
- Website: www.brenus-pharma.com
- Total disclosed funding: $37M
- Latest round: Series A (Jul 20, 2026)
- Investors on record: 10

## About

Based in Lyon, France, and founded in 2014 by co-founders Benoit Pinteur and Jacques Gardette, Brenus Pharma operates as a biotechnology company developing next-generation in vivo immunotherapies for solid tumors. Leveraging its proprietary Stimulated-Ghost-Cells (SGC) platform, the company develops tumor antigen-focused immunotherapies designed to reproduce tumor heterogeneity, reveal resistance mechanisms, and stimulate anti-tumor immune responses. In July 2026, Brenus Pharma raised EUR 11 million in Series A funding & grant from rAngelor, UI Investissement, Crédit Agricole Centre France, Noshaq, Investsud, BIO JAG, Sambrinvest, and Korea Omega Investment Corp and Bpifrance Investissement. The round was part of larger?EUR 33.2 Million series A extension round and grant?funding. As of August 2026, Company is led by Paul Bravetti as CEO and Aymeric Bordet as CFO.
Brenus Pharma develops next-generation in vivo cancer immunotherapies for solid tumors using its proprietary Stimulated-Ghost-Cells (SGC) platform. The company generates off-the-shelf, tumor antigen-focused immunotherapies designed to reproduce tumor heterogeneity, reveal resistance mechanisms, and stimulate a multi-specific immune response against cancer cells. Its lead product candidate, STC-1010, is being developed for colorectal cancer, with additional programs targeting other solid tumors.
Brenus Pharma intends to use the proceeds to advance its lead candidate, STC-1010 (NCT06934538), through Phase I clinical development while further expanding the application of its STC platform across multiple hard-to-treat solid tumour indications. The funding is also expected to support the company's international expansion efforts and help achieve upcoming clinical, operational, and strategic milestones.

## Funding rounds

- Series A, Jul 20, 2026, $13M — UI Investissement, Crédit Agricole Corporate and Investment Bank, Sambrinvest, Noshaq, Korea Omega Investment Corp., Angelor, ORSA
- Series A, Sep 18, 2024, $25M — UI Investissement, Crédit Agricole Centre France, Noshaq, Angelor, Investsud, Crédit agricole Centre-est

## Investors

- UI Investissement (https://capitalatlas.ai/funds/ui-investissement) — Series A
- Crédit Agricole Centre France — Series A
- Noshaq (https://capitalatlas.ai/funds/noshaq) — Series A
- Angelor (https://capitalatlas.ai/funds/angelor) — Series A
- Investsud — Series A
- Crédit agricole Centre-est — Series A
- Crédit Agricole Corporate and Investment Bank — Series A
- Sambrinvest (https://capitalatlas.ai/funds/sambrinvest) — Series A
- Korea Omega Investment Corp. (https://capitalatlas.ai/funds/korea-omega-investment-corp) — Series A
- ORSA (https://capitalatlas.ai/funds/orsa) — Series A